Linda JW Bosch
Linda JW Bosch
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Verified email at - Homepage
Cited by
Cited by
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 …
EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ...
The Lancet Oncology 20 (7), 948-960, 2019
Molecular tests for colorectal cancer screening
LJW Bosch, B Carvalho, RJA Fijneman, CR Jimenez, HM Pinedo, ...
Clinical colorectal cancer 10 (1), 8-23, 2011
Consensus molecular subtype classification of colorectal adenomas
MA Komor, LJW Bosch, G Bounova, AS Bolijn, PM Delis‐van Diemen, ...
The Journal of pathology 246 (3), 266-276, 2018
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers
EMV De Cuba, R Kwakman, M Van Egmond, LJW Bosch, HJ Bonjer, ...
Virchows Archiv 461, 231-243, 2012
Multitarget stool DNA test performance in an average-risk colorectal cancer screening population
LJW Bosch, V Melotte, S Mongera, KLJ Daenen, VMH Coupé, ...
Official journal of the American College of Gastroenterology| ACG 114 (12 …, 2019
Genomic landscape of metastatic colorectal cancer
JC Haan, M Labots, C Rausch, M Koopman, J Tol, LJM Mekenkamp, ...
Nature communications 5 (1), 5457, 2014
Promoter CpG island hypermethylation-and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without …
S Derks, LJW Bosch, HEC Niessen, PTM Moerkerk, SM Van Den Bosch, ...
Carcinogenesis 30 (6), 1041-1048, 2009
DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT
LJW Bosch, FA Oort, M Neerincx, CAJ Khalid-de Bakker, JST sive Droste, ...
Cancer Prevention Research 5 (3), 464-472, 2012
Novel stool-based protein biomarkers for improved colorectal cancer screening: a case–control study
LJW Bosch, M De Wit, TV Pham, VMH Coupé, AC Hiemstra, SR Piersma, ...
Annals of Internal Medicine 167 (12), 855-866, 2017
Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer
A Jacobsen, LJW Bosch, SR Martens-de Kemp, B Carvalho, ...
Scientific reports 8 (1), 7522, 2018
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers
EMV De Cuba, P Snaebjornsson, DAM Heideman, NCT Van Grieken, ...
International journal of cancer 138 (5), 1139-1145, 2016
Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening
I Lansdorp-Vogelaar, SL Goede, LJW Bosch, V Melotte, B Carvalho, ...
Clinical gastroenterology and hepatology 16 (4), 504-512. e11, 2018
Proteins in stool as biomarkers for non‐invasive detection of colorectal adenomas with high risk of progression
MA Komor, LJW Bosch, VMH Coupé, C Rausch, TV Pham, SR Piersma, ...
The Journal of pathology 250 (3), 288-298, 2020
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
SJ Schraa, KL Van Rooijen, DEW Van Der Kruijssen, C Rubio Alarcón, ...
BMC cancer 20, 1-10, 2020
Fecal tests: From blood to molecular markers
GP Young, LJW Bosch
Current colorectal cancer reports 7, 62-70, 2011
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
KG Samsom, LJW Bosch, LJ Schipper, P Roepman, E de Bruijn, LR Hoes, ...
BMC medical genomics 13, 1-7, 2020
Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection
LJW Bosch, S Mongera, JST sive Droste, FA Oort, ST van Turenhout, ...
Cellular oncology 35, 309-315, 2012
Clinical validation of a multitarget fecal immunochemical test for colorectal cancer screening: a diagnostic test accuracy study
W de Klaver, PHA Wisse, F van Wifferen, LJW Bosch, CR Jimenez, ...
Annals of Internal Medicine 174 (9), 1224-1231, 2021
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
ILM Reijers, D Rao, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, ...
Journal of Experimental Medicine 220 (5), e20221952, 2023
Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice
KG Samsom, LJ Schipper, P Roepman, LJW Bosch, F Lalezari, ...
The Journal of pathology 258 (2), 179-188, 2022
The system can't perform the operation now. Try again later.
Articles 1–20